Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Naltrexone/Bupropion SR Tablets from Two Manufacturers
NCT02259179Phase 1Completed
- Sponsor
- Orexigen Therapeutics
- Start
- Sep 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of naltrexone + bupropion in obesity (2 arms), sponsored by Orexigen Therapeutics. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve to Last Quantifiable Concentration and 1 more. Started Sep 2014; status: completed.
02
Drugs
naltrexone + bupropion
03
Conditions
obesity
Beyond the preview
Go deeper on NCT02259179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02259179.